My thoughts exactly! The loss has already occurred...it's done. So from this point forward, would you hold or buy this stock with the possibility of being 3.00 to 6.00 in 2014? I'm staying.
as said before....oppenheimer has big institutional clients at these conferences that will buy into the huge upcoming potential
of OMER. 2014 will be a big year for OMER!
Sentiment: Strong Buy
Agree with mbbf49a and you can see more about cabozantinib under symbol EXEL. Very promising drug.
Live presentation is at 4:45 but we all get a web broadcast at 6:30 EST from GERON website.
"Following Gilead's NDA submission for iNHL, FDA granted idelalisib a Breakthrough Therapy designation for chronic lymphocytic leukemia in relapsed patients. Gilead is now engaging in a dialogue with the FDA regarding a regulatory filing in CLL."....from article today.